VarmX Enters Strategic Collaboration and Option Agreement with CSL to Advance Novel Coagulation Treatment
Wednesday, September 17, 2025
VarmX, a biotechnology company focused on therapies for bypassing direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has formed a strategic collaboration with CSL (ASX: CSL) to advance its lead candidate, VMX-C001. The therapy is designed to restore blood clotting in patients on FXa DOACs who face severe bleeding or require urgent surgery. As part of the arrangement, CSL has also secured an exclusive option agreement with VarmX shareholders to acquire the company.
CSL will fully fund the global Phase 3 EquilibriX-S trial of VMX-C001 in patients treated with FXa DOACs requiring emergency surgery. The company will also support late-stage development, manufacturing, and pre-launch activities.
VarmX shareholders will receive an upfront payment of USD 117 million at the close of the transaction. Following Phase 3 results, CSL may exercise its option to acquire VarmX. The deal could deliver an additional USD 388 million before commercial launch and up to USD 1.7 billion in sales-related milestone payments thereafter.
VMX-C001 is an investigational, recombinant modified Factor X protein given as a single rapid dose. It works by bypassing the anticoagulation effect of FXa inhibitors and quickly restoring coagulation. The treatment has potential to work across all FXa DOACs and alongside other anticoagulants such as heparin, without adding thrombotic risk.
By 2030, around 30 million patients in the US, Europe, and Japan are expected to be on FXa DOACs for conditions such as atrial fibrillation and deep vein thrombosis. Each year, 2–4% of these patients may experience major bleeding or require emergency surgery, representing over 30,000 affected individuals weekly. Despite this clinical need, no fully approved treatment is available in the US or EU for acute bleeding in patients on FXa inhibitors.
The FDA granted Fast Track designation to VMX-C001 on 3 September 2025, highlighting its potential to meet a critical unmet need. Commercial launch is anticipated in 2029.
Source: businesswire.com
